This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/pubchem-compound/
n20http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/national-drug-code-directory/
n18http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/chemspider/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00925/identifier/bindingdb/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00925
rdf:type
n3:Drug
n3:description
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator. [PubChem]
n3:dosage
n27:271B61FA-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/88984 # Frang H, Cockcroft V, Karskela T, Scheinin M, Marjamaki A: Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors. J Biol Chem. 2001 Aug 17;276(33):31279-84. Epub 2001 Jun 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11395517
n3:group
approved
n3:halfLife
24 hours
n3:indication
For the treatment of phaeochromocytoma (malignant), benign prostatic hypertrophy and malignant essential hypertension.
n3:manufacturer
n8:271B61F7-363D-11E5-9242-09173F13E4C5
owl:sameAs
n17:DB00925 n18:DB00925
dcterms:title
Phenoxybenzamine
adms:identifier
n7:Phenoxybenzamine n19:4768 n21:46507191 n22:65197-001-01 n23:PA450919 n24:DB00925 n25:C07435 n26:50017679 n28:4604
n3:mechanismOfAction
Phenoxybenzamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure.
n3:packager
n8:271B61F5-363D-11E5-9242-09173F13E4C5 n8:271B61F6-363D-11E5-9242-09173F13E4C5 n8:271B61F4-363D-11E5-9242-09173F13E4C5
n3:synonym
SID124879342 POB Phenoxybenzamine Fenossibenzamina SID124879343 Dibenzyline Fenoxibenzamina SID104171113 Phenoxybenzaminum
n3:toxicity
Symptoms of overdose are largely the result of block of the sympathetic nervous system and of the circulating epinephrine. They may include postural hypotension resulting in dizziness or fainting, tachycardia, particularly postural, vomiting; lethargy, and shock.
n3:salt
n9:hasConcept
n10:M0016529
foaf:page
n12:phenoxybenzamine.html n20:phenoxybenz.htm
n3:IUPAC-Name
n4:271B61FF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6205-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6204-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6201-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6202-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6203-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61FD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B6215-363D-11E5-9242-09173F13E4C5 n4:271B61FB-363D-11E5-9242-09173F13E4C5 n4:271B61FE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61FC-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:C04AX02
n3:H-Bond-Acceptor-Count
n4:271B620B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B620C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6206-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6207-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6209-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6208-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B620A-363D-11E5-9242-09173F13E4C5
n3:absorption
Twenty to 30 percent of orally administered phenoxybenzamine appears to be absorbed in the active form.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
59-96-1
n3:category
n3:containedIn
n5:271B61F8-363D-11E5-9242-09173F13E4C5 n5:271B61F9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6210-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6212-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6213-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6214-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B620F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B620E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6211-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6200-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B620D-363D-11E5-9242-09173F13E4C5